Close
Close

Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

Descriptive Information
Brief Title † Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
Official Title † Cancer Risk in Xeroderma Pigmentosum Heterozygotes
Brief Summary This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal cancers, or other changes. XP is a rare inherited disease that involves an inability to repair damage to cell DNA (genetic material). It can affect several organ systems, including the skin, eye, nervous system, and bones. Patients have a more than thousand-fold increase in frequency in all major skin cancers. Parents of patients with XP are carriers of the abnormal XP gene. Other family members may also be carriers of the abnormal XP gene. Carriers do not develop the disease themselves; symptoms develop only in children who have inherited the faulty gene from both parents. This study will try to clarify the genetic basis for XP and to understand the increased frequency of cancer in the disease. XP patients who have been evaluated at the NIH Clinical Center and their relatives are eligible for this study. Newly diagnosed XP patients are also eligible. Spouses of relatives will also be included as control subjects. Patients and their family members will undergo some or all of the following procedures: - Parental permission to review the child s relevant medical records and pathology material from treatments or surgery for cancer or other related illnesses - Medical history and physical examination, with particular attention to the skin and possible eye, hearing or neurological examinations - Photographs to document skin and other physical findings - Nuclear medicine scans to evaluate the brain and nervous system - X-rays of the skull or other parts of the body - Nervous system testing with an electroencephalogram (EEG), electroretinogram (ERG), electromyogram (EMG) or nerve conduction velocity measurement - Collection of blood and skin samples for gene studies - Establishment of cell lines from collected blood or tissues to study DNA repair, skin cancer, cancers related to XP, immune defects, and related studies. - Biopsy (surgical removal of a small piece of tissue) of suspicious skin lesions for examination under a microscope - Collection of a cheek cell sample, obtained by twirling a soft brush against the inside of the cheek - Collection of a hair sample for microscopic examination and composition analysis - Surgery to treat skin cancers or other lesions
Detailed Description Xeroderma Pigmentosum (XP) is a rare, recessive disorder with a more than 1000-fold increase in the frequency of all major skin cancers in association with defective DNA repair. The risk of skin and other cancers among normal appearing XP heterozygote individuals has not been fully studied. We plan to study the family members from XP families with known DNA repair gene mutations to determine if heterozygote carriers of XP disease mutations are at an increased risk of developing cancer. For controls we will compare XP heterozygotes to their non-carrier blood relatives and spouses and to the Surveillance, Epidemiology and End Results (SEER) rates. For this purpose, blood, skin or buccal cells will be obtained from all available relatives for DNA or RNA mutation analysis. Cancer confirmation will be accomplished through review of pathology reports, medical records and death certificates. In addition, willing family members will be clinically examined to determine current cancer status. Individuals who are determined to be heterozygous carriers of XP DNA repair gene disease mutations in these families by mutation analysis or by pedigree will be compared to non-carrier relatives and spouses with respect to history of any type of cancer. We will also focus on skin cancer and cancer of the nervous system since the risks of these cancers are elevated among the XP homozygotes.
Study Phase N/A
Study Type † Observational
Study Design †
Primary Outcome Measure † Determine increased risk of developing cancer
Secondary Outcome Measure †
Condition † Xeroderma Pigmentosum Melanoma Squamous Cell Carcinoma Basal Cell Carcinoma Skin Cancer
Intervention †
Study Arms / Comparison Groups
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status †
Estimated Enrollment † 800
Start Date † September 18, 2002
Completion Date
Primary Completion Date
Eligibility Criteria † - INCLUSION CRITERIA: Members of the XP families where the proband has previously been evaluated at the Clinical Center or is newly diagnosed under other approved protocols (primarily 99-C-0099) are eligible to participate in this study. Families with XP patients of any age, gender or race are eligible for this study. - On referral, families of XP patients will be considered for inclusion in the study if the proband has clinical documentation of features of XP and laboratory determination of the DNA repair defect. All relatives of XP patients including spouses are eligible to participate. A spouse of a blood relative of a patient with xeroderma pigmentosum would also be eligible. - Ability of patient or Legally Authorized Representative (LAR) to sign a written informed consent document EXCLUSION CRITERIA: -Inability or unwillingness to provide family history information or tissue (skin, blood, buccal cells or hair) for laboratory studies.
Gender All
Ages 1 Year - 99 Years
Accepts Healthy Volunteers Accepts Healthy Volunteers
Contacts †† Kenneth H Kraemer, M.D., (240) 760-6139, kraemerk@mail.nih.gov
Location Countries † United States
Administrative Information
NCT ID † NCT00046189
Organization ID 020313
Secondary IDs †† 02-C-0313
Responsible Party Sponsor
Study Sponsor † National Cancer Institute (NCI)
Collaborators ††
Investigators † Principal Investigator: Kenneth H Kraemer, M.D., National Cancer Institute (NCI)
Information Provided By
Verification Date September 23, 2016
First Received Date † September 21, 2002
Last Updated Date April 21, 2017
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
Free Newsletter